Imfinzi package insert / prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions and pharmacology.
Imfinzi (durvalumab) is a type of immunotherapy used to treat types of lung cancer (NSCLC, SCLC), biliary tract cancer (BTC), hepatocellular carcinoma, and endometrial cancer. Includes Imfinzi side effects, interactions, indications. and package insert.
(U.S. Food and Drug Administration 2024). Policy Imfinzi (durvalumab) is Imfinzi [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP
Imfinzi 500 mg/10 mL single-dose vial: xx. VII. References. 1. Imfinzi [package insert]. Wilmington, DE; AstraZeneca
IMFINZI CONCENTRATE FOR SOLUTION FOR INTRAVENOUS INFUSION 50 MG/ML Proposed Package Insert / Sisipan Bungkusan. No, Attachment. 1, MY-Package
Treatment of unresectable hepatocellular carcinoma (as a single agent or in combination with tremelimumab) in adults. Imfinzi [package insert]. Wilmington, DE
Package Insert. CONTROLLED MEDICINE. MAL ACZ. BRU PS2 IMFINZI is a registered trademark of the AstraZeneca group of
by HJ Ipema 2024 Cited by 1Defitelio [package insert]. Palo Alto, CA: Jazz Pharmaceuticals Inc; 2024. [Google Scholar]. 72. Imfinzi [package insert]. Wilmington, DE: AstraZeneca
Revisions of Drug Package Inserts PMDA Alert for Proper Use of Drugs PMDA Imfinzi Initial Approval, Durvalumab (genetical recombination), July 2024
I would like to know more about this package. ^.^